Lee Dong-hoon, CEO of SK Biopharm, has purchased 180 million won (approximately $1.8 million) worth of company shares, a move interpreted as a demonstration of management's confidence in the company's growth.
SK Biopharm announced on the 31st that Lee acquired 2,000 common shares on the 27th at an average price of 90,898 won per share.
This purchase occurred the day after the company revealed the introduction of its next-generation global drug candidate, 'Opacalim.' SK Biopharm plans to develop Opacalim as a key growth driver following Cenobamate.
The company stated, "This reflects management's commitment to long-term growth based on the solid growth of Cenobamate and the next-generation growth drivers, including Opacalim."
Yoo Chang-ho, head of the strategy division who led the Opacalim licensing agreement, also participated in responsible management by purchasing 500 shares of the company.
Additionally, SK Biopharm has announced a global exclusive licensing agreement with Biohaven Pharmaceuticals for the epilepsy drug candidate Opacalim and other Kv7 activator compounds, with a contract value of up to $795 million (approximately 1 trillion won).
Opacalim is being developed as a new drug candidate targeting partial seizures in epilepsy patients. It works by activating the Kv7 potassium channels that regulate neuronal excitability. Clinical trials, including 'RISE2' and 'RISE3,' are currently underway, with topline results from RISE3 expected to be announced in the second half of this year.
SK Biopharm announced on the 31st that Lee acquired 2,000 common shares on the 27th at an average price of 90,898 won per share.
This purchase occurred the day after the company revealed the introduction of its next-generation global drug candidate, 'Opacalim.' SK Biopharm plans to develop Opacalim as a key growth driver following Cenobamate.
The company stated, "This reflects management's commitment to long-term growth based on the solid growth of Cenobamate and the next-generation growth drivers, including Opacalim."
Yoo Chang-ho, head of the strategy division who led the Opacalim licensing agreement, also participated in responsible management by purchasing 500 shares of the company.
Additionally, SK Biopharm has announced a global exclusive licensing agreement with Biohaven Pharmaceuticals for the epilepsy drug candidate Opacalim and other Kv7 activator compounds, with a contract value of up to $795 million (approximately 1 trillion won).
Opacalim is being developed as a new drug candidate targeting partial seizures in epilepsy patients. It works by activating the Kv7 potassium channels that regulate neuronal excitability. Clinical trials, including 'RISE2' and 'RISE3,' are currently underway, with topline results from RISE3 expected to be announced in the second half of this year.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.